Immediate-Type Hypersensitivity Cross-Reactions to Proton Pump Inhibitors: A Descriptive Study of Data from the French National Pharmacovigilance Database.


Journal

International archives of allergy and immunology
ISSN: 1423-0097
Titre abrégé: Int Arch Allergy Immunol
Pays: Switzerland
ID NLM: 9211652

Informations de publication

Date de publication:
Historique:
received: 29 03 2018
accepted: 10 09 2018
pubmed: 30 11 2018
medline: 22 5 2019
entrez: 29 11 2018
Statut: ppublish

Résumé

Proton pump inhibitors (PPIs) can trigger immediate-type hypersensitivity reactions (HSRs). Three main patterns of cross-reactivity have been identified: reactions to a single PPI, selective cross-reactions, and cross-reactions with all PPIs. Several hypotheses have been advanced, but no consensus has been reached. We sought to identify immediate-type hypersensitivity cross-reactions to PPIs using real-world data about hypersensitivity testing from French pharmacovigilance cases. Potentially relevant immediate-type HSRs reported from January 1985 to February 2015 were extracted from the French pharmacovigilance database using a standardized MedDRA query (SMQ). Cases describing skin tests or oral provocation tests (OPTs) performed with several PPIs that yielded at least one positive result were included. The SMQ extracted 2,119 cases, 38 of which were included in our study. Data collected from skin tests and OPTs indicated cross-reactions with all PPIs (n = 1), reactions to a single PPI (n = 14), or selective cross-reactions (n = 23). Esomeprazole, omeprazole, and pantoprazole concerned 78% of all selective cross-reactions. In more than half of the cases (55.3%), only 2 PPIs were tested. To the best of our knowledge, this PPI cross-reactivity study is the largest to date in terms of population size, describing 38 immediate-type HSRs to PPIs explored by skin tests or OPTs. This paucity of data belies the lack of standardized procedures for PPI hypersensitivity testing. It is likely that PPI HSR workups in everyday clinical practice are often incomplete. Further research to gain insight into selective cross-reactions between PPIs is needed. In the meantime, thorough workups should be completed when a PPI is suspected to have triggered an HSR, instead of routine contraindication to all PPIs.

Sections du résumé

BACKGROUND BACKGROUND
Proton pump inhibitors (PPIs) can trigger immediate-type hypersensitivity reactions (HSRs). Three main patterns of cross-reactivity have been identified: reactions to a single PPI, selective cross-reactions, and cross-reactions with all PPIs. Several hypotheses have been advanced, but no consensus has been reached.
OBJECTIVE OBJECTIVE
We sought to identify immediate-type hypersensitivity cross-reactions to PPIs using real-world data about hypersensitivity testing from French pharmacovigilance cases.
METHODS METHODS
Potentially relevant immediate-type HSRs reported from January 1985 to February 2015 were extracted from the French pharmacovigilance database using a standardized MedDRA query (SMQ). Cases describing skin tests or oral provocation tests (OPTs) performed with several PPIs that yielded at least one positive result were included.
RESULTS RESULTS
The SMQ extracted 2,119 cases, 38 of which were included in our study. Data collected from skin tests and OPTs indicated cross-reactions with all PPIs (n = 1), reactions to a single PPI (n = 14), or selective cross-reactions (n = 23). Esomeprazole, omeprazole, and pantoprazole concerned 78% of all selective cross-reactions. In more than half of the cases (55.3%), only 2 PPIs were tested.
CONCLUSION CONCLUSIONS
To the best of our knowledge, this PPI cross-reactivity study is the largest to date in terms of population size, describing 38 immediate-type HSRs to PPIs explored by skin tests or OPTs. This paucity of data belies the lack of standardized procedures for PPI hypersensitivity testing. It is likely that PPI HSR workups in everyday clinical practice are often incomplete. Further research to gain insight into selective cross-reactions between PPIs is needed. In the meantime, thorough workups should be completed when a PPI is suspected to have triggered an HSR, instead of routine contraindication to all PPIs.

Identifiants

pubmed: 30485850
pii: 000493581
doi: 10.1159/000493581
doi:

Substances chimiques

Proton Pump Inhibitors 0

Types de publication

Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

159-166

Informations de copyright

© 2018 S. Karger AG, Basel.

Auteurs

Caroline Tourillon (C)

Clinical Pharmacology Department, Institute of Biology, CHU Nantes, Nantes, France.

Julien Mahe (J)

Clinical Pharmacology Department, Institute of Biology, CHU Nantes, Nantes, France, julien.mahe@chu-nantes.fr.

Aurélie Baron (A)

Pneumology Department, CHU Nantes, Nantes, France.

Aude Lambert (A)

Clinical Pharmacology Department, CHRU Strasbourg, Strasbourg, France.

Mélissa Yélehé-Okouma (M)

Clinical Pharmacology Department, CHRU Nancy, Nancy, France.

Gwenaelle Veyrac (G)

Clinical Pharmacology Department, Institute of Biology, CHU Nantes, Nantes, France.

Pascale Jolliet (P)

Clinical Pharmacology Department, Institute of Biology, CHU Nantes, Nantes, France.
INSERM U1246 SPHERE "methodS in Patient-centered outcomes and HEalth ResEarch," Institute of Health Research IRS, Nantes University, Nantes, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH